Literature DB >> 8501507

Peptides and the primary afferent nociceptor.

J D Levine1, H L Fields, A I Basbaum.   

Abstract

An expanding knowledge of neuropeptides and their function has led to a profound change in our view of how the PAN contributes to pain. In addition to their expected direct action on postsynaptic cells in the dorsal horn, neuropeptides can modify transmitter release from nearby terminals of other PANs and/or diffuse to act on dorsal horn neurons at a considerable distance from their site of release (Fig. 2). Contrary to early expectations and despite the evidence that several neuropeptides excite central nociceptive neurons, there is no clear correspondence between neuropeptide content and physiologically defined classes of small-diameter primary afferents. There is, however, a tendency for populations of afferents innervating different organs to differ consistently in their peptide content. In fact, the peptide content of primary afferents is, in part, determined by specific factors in the tissues that they innervate. Furthermore, peptide content can change dramatically in response to certain prolonged stimuli or nerve damage. The lack of correspondence of peptide content and physiological response pattern, the plasticity of peptide content, its tissue specificity, and the possibility for action at a distance from the site of their release from central PAN terminals strongly suggest that PAN peptides have functions that are fundamentally different from those of the short-range actions of amino acid neurotransmitters that are also found in the PAN. Finally, nowhere is the plasticity of function of the PAN more evident than at its peripheral terminals. Long-term changes are produced in these terminals by a host of peptides that derive from a variety of cell types. The complexity of this transduction process is augmented by the activity-induced release of peripherally active neuropeptides from the PAN itself. In addition to the variety of fundamental neurobiological issues that recent studies of PANs have raised, they have also generated a great deal of clinical interest, in view of the role of the PAN in inflammation and its accessibility for study and for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8501507      PMCID: PMC6576482     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  68 in total

1.  delta opioid receptor modulation of several voltage-dependent Ca(2+) currents in rat sensory neurons.

Authors:  C G Acosta; H S López
Journal:  J Neurosci       Date:  1999-10-01       Impact factor: 6.167

2.  A sensory neuron subpopulation with unique sequential survival dependence on nerve growth factor and basic fibroblast growth factor during development.

Authors:  C G Acosta; A R Fábrega; D H Mascó; H S López
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

Review 3.  What is the role of NSAIDs in pre-emptive analgesia?

Authors:  E Andrew Ochroch; Issam A Mardini; Allan Gottschalk
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Transient receptor potential channels in pain and inflammation: therapeutic opportunities.

Authors:  Mark A Schumacher
Journal:  Pain Pract       Date:  2010-03-02       Impact factor: 3.183

Review 5.  The pain of tendinopathy: physiological or pathophysiological?

Authors:  Ebonie Rio; Lorimer Moseley; Craig Purdam; Tom Samiric; Dawson Kidgell; Alan J Pearce; Shapour Jaberzadeh; Jill Cook
Journal:  Sports Med       Date:  2014-01       Impact factor: 11.136

6.  Regulation of prostacyclin and prostaglandin E(2) receptor mediated responses in adult rat dorsal root ganglion cells, in vitro.

Authors:  D K Rowlands; C Kao; H Wise
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

7.  Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons.

Authors:  S B Oh; P B Tran; S E Gillard; R W Hurley; D L Hammond; R J Miller
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

8.  Kainate receptors are primarily postsynaptic to SP-containing axon terminals in the trigeminal dorsal horn.

Authors:  Deborah M Hegarty; Jennifer L Mitchell; Kristin C Swanson; Sue A Aicher
Journal:  Brain Res       Date:  2007-10-04       Impact factor: 3.252

9.  Chronic Daily Headache: Theory to Therapy.

Authors: 
Journal:  Curr Rev Pain       Date:  1999

10.  Activation of peripheral and spinal histamine H3 receptors inhibits formalin-induced inflammation and nociception, respectively.

Authors:  Keri E Cannon; Rob Leurs; Lindsay B Hough
Journal:  Pharmacol Biochem Behav       Date:  2007-07-25       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.